According to the National Gaucher Foundation, Gaucher disease is one of the most common lysosomal storage disorders and results from lacking enough glucocerebrosidase (GCase), an important enzyme that breaks down a fatty chemical called glucocerebroside because the body cannot break down this chemical, fat-laden Gaucher cells build up in areas like the spleen, liver, and bone marrow.
Current treatment of Gaucher’s Disease includes enzyme replacement therapies (ERTs) and substrate reduction therapies (SRTs). Potential treatments under investigation include newer SRTs, pharmacological chaperone therapies (PCTs), and histone deacetylase inhibitors (HDACIs).
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/gauchers-disease-market
The Gaucher’s Disease market report also covers emerging drugs, current treatment practices, Gaucher’s Disease market share of the individual therapies, current and forecasted Gaucher’s Disease Market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Gaucher’s Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Gaucher’s Disease Market Key Facts
-
As per the study conducted by Weinreb et al. titled “Prevalence of Type 1 Gaucher Disease in the United States” the prevalence of type 1 GD is 1:40 000 to 60,000 in the general population and 1:500 to 800 among Ashkenazi Jews.
-
A Spanish-based study by Giraldo et al. titled “Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula,” found that the prevalence of GD was 1 per 149,000 inhabitants; 88.3% were type 1, 6.7% type 2, and 5.0% type 3.
Key Benefits of Gaucher’s Disease Market Report
-
Gaucher’s Disease market report provides an in-depth analysis of Gaucher’s Disease Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
-
The Gaucher’s Disease market report will help in developing business strategies by understanding the Gaucher’s Disease Market trends & developments, key players, and future market competition that will shape and drive the Gaucher’s Disease market in the upcoming years.
-
The Gaucher’s Disease market report covers Gaucher’s Disease current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Gaucher’s Disease market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
Gaucher Disease market size is anticipated to increase during the study period owing to the increasing prevalent population of Gaucher Disease patients in the 7MM countries. The launch of the upcoming therapies across all geographies will also fuel the market growth.
The Gaucher’s Disease market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Gaucher’s Disease market trends by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Gaucher’s Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Gaucher’s Disease Epidemiology
The Gaucher’s Disease epidemiology section covers insights about the historical and current Gaucher’s Disease patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Gaucher’s Disease Drugs Uptake and Key Market Players
The Gaucher’s Disease Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gaucher’s Disease market or expected to get launched in the market during the study period. The analysis covers Gaucher’s Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Research is underway to identify treatment approaches that may address some of the challenges to existing Gaucher’s Disease treatment.
Key players involved in developing therapies for the treatment of Gaucher Disease include:
Sanofi
Genzyme
Orphazyme
Avro Bio
Pfizer
And many others.
Gaucher’s Disease therapies covered in the report include:
Venglustat
Arimoclomol
AVR-RD-02
Cerezyme
Cerdelga
Elelyso
And many more.
Table of Content
1. Key Insights
2. Executive Summary
3. Gaucher’s Disease Competitive Intelligence Analysis
4. Gaucher’s Disease Market Overview at a Glance
5. Gaucher’s Disease Disease Background and Overview
6. Gaucher’s Disease Patient Journey
7. Gaucher’s Disease Epidemiology and Patient Population
8. Gaucher’s Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Gaucher’s Disease Unmet Needs
10. Key Endpoints of Gaucher’s Disease Treatment
11. Gaucher’s Disease Marketed Products
12. Gaucher’s Disease Emerging Therapies
13. Gaucher’s Disease Seven Major Market Analysis
14. Attribute Analysis
15. Gaucher’s Disease Market Outlook (7 major markets)
16. Gaucher’s Disease Access and Reimbursement Overview
17. KOL Views on the Gaucher’s Disease Market.
18. Gaucher’s Disease Market Drivers
19. Gaucher’s Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Lates Reports By DelveInsight –
Italy Healthcare Market Outlook
DelveInsight’s, “Italy Healthcare Outlook Report, 2020,” report provides comprehensive insights about healthcare scenario, regulatory policies and reimbursement landscape in Italy. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of Italy.
Latest Healthcare Blog – Companies in Digestive Disorders Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/